Generic Medicine Info
Indications and Dosage
Susceptible infections
Adult: 600 mg daily as a single or in 2 divided doses for 5-10 days.
Child: ≥6 mth 14 mg/kg daily as a single or in 2 divided doses. Max: 600 mg daily.
Renal Impairment
CrCl (mL/min) Dosage
<30 300 mg once daily.
May be taken with or without food.
Reconstitute powd for oral susp at the time of dispensing by adding the amount of water specified on the container to provide a susp containing 125 mg or 250 mg per 5 mL. Add water in 2 equal parts, invert and shake the bottle after each addition.
Hypersensitivity to cefdinir or other cephalosporins.
Special Precautions
Patient w/ history of penicillin allergy and colitis. Renal impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, nausea, abdominal pain, vomiting, headache, skin rash, vulvovaginal candidiasis, proteinuria, elevated urine leukocytes, lymphocytosis, decreased serum bicarbonate, increased serum ALT and urine specific gravity.
Potentially Fatal: Anaphylaxis, Clostridium difficile-associated diarrhoea and colitis.
Monitoring Parameters
Monitor renal function; observe for signs and symptoms of anaphylaxis during 1st dose.
Symptoms: Nausea, vomiting, epigastric distress, diarrhoea, convulsions. Management: Haemodialysis may be useful in the event of a serious toxic reaction particularly if renal function is compromised.
Drug Interactions
Concomitant admin w/ antacids or Fe supplements reduce the rate and extent of absorption. Admin w/ Fe supplements may cause reddish stools. Decreased renal elimination w/ probenecid.
Lab Interference
False-positive reaction for urinary ketones may occur w/ nitroprusside-based tests. False-positive urine glucose results may occur when using Clinitest®, Benedict's or Fehling's soln. May cause positive direct Coombs' test.
Description: Cefdinir binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Absorption: Absorbed from the GI tract. Bioavailability: Approx 16-25%. Time to peak plasma concentration: 2-4 hr.
Distribution: Widely distributed into body tissues. Volume of distribution: 0.35 L/kg. Plasma protein binding: 60-70%.
Metabolism: Minimal metabolism.
Excretion: Via urine (approx 12-18% as unchanged drug). Elimination half-life: 1.7 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cefdinir, CID=6398970, https://pubchem.ncbi.nlm.nih.gov/compound/Cefdinir (accessed on Jan. 21, 2020)

Store between 20-25°C.
MIMS Class
Anon. Cefdinir. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/11/2014.

Buckingham R (ed). Cefdinir. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/11/2014.

Cefdinir capsule (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/11/2014.

Cefdinir Powder for Suspension (Lupin Pharmaceuticals Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Cefdinir. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/11/2014.

Disclaimer: This information is independently developed by MIMS based on Cefdinir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • Omnicef/Omnicef POS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in